Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. [electronic resource]
Producer: 20110912Description: 401-12 p. digitalISSN:- 1365-2141
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Benzenesulfonates -- pharmacology
- Cell Cycle -- drug effects
- Cell Death -- drug effects
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical -- methods
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Mitogen-Activated Protein Kinase 14 -- antagonists & inhibitors
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Phosphorylation
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Pyridines -- pharmacology
- Signal Transduction -- drug effects
- Sorafenib
- Tumor Cells, Cultured
- Tumor Stem Cell Assay -- methods
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.